206559-39-9

Basic information

• Product Name: 4-BROMO-2-CHLOROBENZHYDRAZIDE
• Synonyms: 4-BROMO-2-CHLOROBENZHYDRAZIDE;4-bromo-2-chlorobenzohydrazide
• CAS NO: 206559-39-9
• Molecular Formula: C7H6BrClN2O
• Molecular Weight: 249.49
• Mol File: 206559-39-9.mol
• Article Data: 1

Chemical Properties

• Melting Point: 173 °C
• Appearance: /
• Density: 1.719 g/cm³
• Refractive Index: 1.626
• CAS DataBase Reference: 4-BROMO-2-CHLOROBENZHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-CHLOROBENZHYDRAZIDE(206559-39-9)
• EPA Substance Registry System: 4-BROMO-2-CHLOROBENZHYDRAZIDE(206559-39-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 206559-39-9(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-chlorobenzhydrazide is a chemical compound with the formula C7H6BrClN2O. It is an organic compound used in the synthesis of pharmaceuticals and agrochemicals. 4-BROMO-2-CHLOROBENZHYDRAZIDE is also used as a reagent in the preparation of other organic compounds, such as the synthesis of benzhydrazone derivatives. It is a white to off-white solid with a melting point of 218-220 degrees Celsius and is sparingly soluble in water and most organic solvents. 4-Bromo-2-chlorobenzhydrazide is classified as a hazardous chemical and can cause irritation to the eyes, skin, and respiratory system, and should be handled with care and proper protective measures.

InChI:InChI=1/C7H6BrClN2O/c8-4-1-2-5(6(9)3-4)7(12)11-10/h1-3H,10H2,(H,11,12)

Upstream product

• 59748-90-2 4-Bromo-2-chloro-benzoic Acid 
• 185312-82-7 4-bromo-2-chlorobenzoic acid methyl ester 

Relevant articles and documents

5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma

Through a phenotypic high-throughput screen using a serum response element luciferase promoter, we identified a novel 5-aryl-1,3,4-oxadiazol-2-ylthiopropionic acid lead inhibitor of Rho/myocardin-related transcription factor (MRTF)/serum response factor (SRF)-mediated gene transcription with good potency (IC50 = 180 nM). We were able to rapidly improve the cellular potency by 5 orders of magnitude guided by sharply defined and synergistic SAR. The remarkable potency and depth of the SAR, as well as the relatively low molecular weight of the series, suggests, but does not prove, that binding to the unknown molecular target may be occurring through a covalent mechanism. The series nevertheless has no observable cytotoxicity up to 100 μM. Ensuing pharmacokinetic optimization resulted in the development of two potent and orally bioavailable anti-fibrotic agents that were capable of dose-dependently reducing connective tissue growth factor gene expression in vitro as well as significantly reducing the development of bleomycin-induced dermal fibrosis in mice in vivo.